Zhi-Yong Du1, Ren-Yi Qin, Wei Xia, Rui Tian, Manoj Kumar. 1. Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China. ryqin@tjh.tjmu.edu.cn
Abstract
AIM: To investigate the therapeutic effect of somatostatin receptor type 2 (SSTR2) gene transfection on pancreatic carcinoma xenografts in vivo in experimental cancers. METHODS: Human pancreatic cancer cell line Panc-1 was inoculated subcutaneously into the back of nude mice. When tumor nodules were grown as large as about 5 mmX5 mm days after inoculation, the mice were randomly divided into 3 groups (6 mice in each group). Group I served as untreated control group. Group II received an intratumoral injection of a combination of human cytomegalovirus promoter-6C (pCMV-6C) and lipofectamine 2000. Group III received an intratumoral injection of a combination of pCMV-6C-SSTR2 and lipofectamine 2000. The rate of tumor growth was compared among these three groups. The expression of SSTR2 in these tumors was detected by immunohistochemistry and Western-blot. Apoptosis index (AI) in these tumors was examined by using TUNEL in situ. RESULTS: Intratumoral injection of a combination of pCMV-6C-SSTR2 and lipofectamine 2000 resulted in the expression of SSTR2 protein. The tumor size and weight in group III (0.318+/-0.098 cm3, and 0.523+/-0.090 g, respectively) were significantly lower than those in group I (2.058+/-0.176 cm3, and 1.412+/-0.146 g, respectively) and group II (2.025+/-0.163 cm3, and 1.365+/-0.116 g, respectively) (P<0.05) The AI in group III (1.47+/-0.13%) was significantly higher than that in group I (0.56+/-0.09%) and group II (0.57+/-0.11%) (P<0.05). But there were no significant differences between groups I and II. CONCLUSION: Our data demonstrate that re-expression of SSTR2 gene has antitumor effects on experimental pancreatic cancer. Restoration of SSTR2 gene expression through gene transfer in vivo might be a potential gene therapy strategy for human pancreatic cancer.
AIM: To investigate the therapeutic effect of somatostatin receptor type 2 (SSTR2) gene transfection on pancreatic carcinoma xenografts in vivo in experimental cancers. METHODS:Humanpancreatic cancer cell line Panc-1 was inoculated subcutaneously into the back of nude mice. When tumor nodules were grown as large as about 5 mmX5 mm days after inoculation, the mice were randomly divided into 3 groups (6 mice in each group). Group I served as untreated control group. Group II received an intratumoral injection of a combination of human cytomegalovirus promoter-6C (pCMV-6C) and lipofectamine 2000. Group III received an intratumoral injection of a combination of pCMV-6C-SSTR2 and lipofectamine 2000. The rate of tumor growth was compared among these three groups. The expression of SSTR2 in these tumors was detected by immunohistochemistry and Western-blot. Apoptosis index (AI) in these tumors was examined by using TUNEL in situ. RESULTS: Intratumoral injection of a combination of pCMV-6C-SSTR2 and lipofectamine 2000 resulted in the expression of SSTR2 protein. The tumor size and weight in group III (0.318+/-0.098 cm3, and 0.523+/-0.090 g, respectively) were significantly lower than those in group I (2.058+/-0.176 cm3, and 1.412+/-0.146 g, respectively) and group II (2.025+/-0.163 cm3, and 1.365+/-0.116 g, respectively) (P<0.05) The AI in group III (1.47+/-0.13%) was significantly higher than that in group I (0.56+/-0.09%) and group II (0.57+/-0.11%) (P<0.05). But there were no significant differences between groups I and II. CONCLUSION: Our data demonstrate that re-expression of SSTR2 gene has antitumor effects on experimental pancreatic cancer. Restoration of SSTR2 gene expression through gene transfer in vivo might be a potential gene therapy strategy for humanpancreatic cancer.
Authors: F G Sturtz; K Waddell; J Shulok; X Chen; M Caruso; M Sanson; H R Snodgrass; D Platika Journal: Hum Gene Ther Date: 1997-11-01 Impact factor: 5.695
Authors: Amor Hajri; Séverine Wack; Pierre Lehn; Jean-Pierre Vigneron; Jean-Marie Lehn; Jacques Marescaux; Marc Aprahamian Journal: Cancer Gene Ther Date: 2004-01 Impact factor: 5.987
Authors: J G Klijn; A M Hoff; A S Planting; J Verweij; T Kok; S W Lamberts; H Portengen; J A Foekens Journal: Br J Cancer Date: 1990-10 Impact factor: 7.640
Authors: Laura G Franko-Tobin; L Vienna Mackey; Wei Huang; Xiangwei Song; Baofeng Jin; Jing Luo; Lynsie M Morris; Minqiu Liu; Joseph A Fuselier; David H Coy; Lizi Wu; Lichun Sun Journal: Oncologist Date: 2012-01-30
Authors: M Kilian; J I Gregor; I Heukamp; K Helmecke; M Hanel; B Wassersleben; M K Walz; I Schimke; G Kristiansen; F A Wenger Journal: Clin Exp Metastasis Date: 2009-06-12 Impact factor: 5.150